Bg pattern

RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Ruconest 2100 units powder for solution for injection

conestat alfa

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Ruconest and what is it used for
  2. What you need to know before you use Ruconest
  3. How to use Ruconest
  4. Possible side effects
  5. Storage of Ruconest
  6. Contents of the pack and other information

1. What is Ruconest and what is it used for

Ruconest contains conestat alfa as the active substance. Conestat alfa is a recombinant (non-blood-derived) form of human C1 inhibitor (rhC1-INH).

Ruconest should be used by adults, adolescents, and children (from 2 years of age) with a rare hereditary blood disorder called hereditary angioedema (HAE). These patients have a deficiency of the C1 inhibitor protein in their blood, which can cause repeated episodes of swelling, abdominal pain, difficulty breathing, and other symptoms.

Administration of Ruconest resolves the deficiency of C1 inhibitor and allows a reduction of the symptoms of acute HAE attacks.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Ruconest

Do not use Ruconest

  • If you are or are considered to be allergic to rabbits.
  • If you are allergic to conestat alfa or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor before you start using Ruconest.

If you experience allergic reactions, such as hives, rash, itching, dizziness, wheezing, difficulty breathing, or swelling of the tongue after administration of Ruconest, seek emergency medical attention to treat the symptoms of the allergic reaction urgently.

Children and adolescents

Do not administer this medicine to children under 2 years of age. Ruconest has not been studied in children under 5 years of age. Your doctor will determine if treatment with Ruconest is suitable for your child. Additional monitoring of your child is required to detect symptoms of allergic reactions during and after administration.

Using Ruconest with other medicines

Tell your doctor if you are using, have recently used, or might use any other medicines.

If you receive tissue plasminogen activator as acute treatment for the prevention of blood clots (anticoagulant treatment), you should not use Ruconest at the same time.

Pregnancy and breastfeeding

Ruconest should not be administered during pregnancy or breastfeeding.

If you plan to become pregnant, consult your doctor before using Ruconest.

Driving and using machines

Do not drive or operate machinery if you feel dizzy or have a headache after using Ruconest.

Ruconest contains sodium (19.5 mg per vial)

Patients on low-sodium diets should be aware that this medicine contains 19.5 mg of sodium per vial.

3. How to use Ruconest

Treatment with Ruconest will be started by a doctor who is specialized in the diagnosis and treatment of hereditary angioedema.

Your doctor or a nurse will administer Ruconest directly into a vein over approximately 5 minutes. The dose, up to 2 vials, will depend on your weight.

Most of the time, one dose is sufficient. Your doctor may decide to administer an additional dose if your symptoms do not improve after 120 minutes (for adults and adolescents) or 60 minutes (for children). No more than two doses can be administered within a 24-hour period.

The instructions for use are described clearly in the physician's information leaflet and are attached.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If your symptoms worsen and/or you experience rash, tingling, difficulty breathing, or swelling of the face or tongue, go to the doctor immediately. These symptoms may indicate that you have developed an allergy to Ruconest.

During treatment with Ruconest, some side effects may occur:

Common: may affect up to 1 in 10 people

  • Nausea

Uncommon: may affect up to 1 in 100 people

  • Abdominal pain, diarrhea
  • Feeling of tingling, pins and needles, or numbness in the mouth
  • Headache, dizziness
  • Decreased sense of touch or sensitivity in the skin or extremities
  • Throat irritation
  • Hives (urticaria)
  • Swelling of the ears or the area around the ears

Reporting of side effects

If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Ruconest

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the vial after CAD/EXP. The expiry date is the last day of the month shown.

Do not store above 25°C.

Store in the original package to protect from light.

Ruconest should be dissolved in water for injections before administration by a healthcare professional.

Once reconstituted, the product should be used immediately.

Do not use this medicine if you notice that the solution contains particles or if the solution is discolored.

6. Contents of the pack and other information

Composition of Ruconest

The active substance is conestat alfa. One vial contains 2100 units (U) of conestat alfa. This is equivalent to 2100 units per 14 ml after reconstitution, or a concentration of 150 units/ml.

The other ingredients are sucrose, sodium citrate (E331), and citric acid.

Appearance and pack size

Ruconest is presented as a single glass vial containing a white to off-white powder for solution for injection. After dissolution of the powder in water for injections, the solution is clear and colorless.

Ruconest is supplied in a carton containing one vial.

Marketing authorisation holder and manufacturer

Marketing authorisation holder:

Pharming Group N.V.

Darwinweg 24

2333 CR Leiden

Netherlands

Manufacturer:

Pharming Technologies B.V.

Darwinweg 24

2333 CR Leiden

Netherlands

Date of last revision of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu/.

This information is intended only for healthcare professionals:

DOSAGE AND ADMINISTRATION

Dosage

Body weight up to 84 kg

  • An intravenous injection of 50 U/kg body weight.

Body weight 84 kg or more

  • An intravenous injection of 4200 U (two vials).

In most cases, a single injection of Ruconest is sufficient for the treatment of an acute attack of hereditary angioedema.

If the clinical response is insufficient, a second dose (50 U/kg body weight up to 4200 U) may be administered.

No more than two doses can be administered within a 24-hour period.

Dose calculation

Determine the patient's body weight.

Body weight up to 84 kg

  • In patients up to 84 kg body weight, the volume to be administered will be calculated using the following formula:

Volume to be administered (ml)

=

Body weight (kg) x 50 (U/kg)

150 (U/ml)

=

Body weight (kg)

3

Body weight 84 kg or more

  • In patients 84 kg or more, the volume to be administered is 28 ml, equivalent to 4200 U (2 vials).

Reconstitute each vialwith 14 ml of water for injections (see section Reconstitution below).

The reconstituted solution in each vial contains 2100 U of conestat alfa at 150 U/ml.

The required volume of the reconstituted solution should be administered by slow intravenous injection over approximately 5 minutes.

SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

Each vial of Ruconest is for single use.

Aseptic technique should be used for reconstitution, combination, and mixing of solutions.

Reconstitution

Each vial of Ruconest (2100 U) should be reconstituted with 14 ml of water for injections. The water for injections should be added slowly to avoid a strong impact on the powder and mixed gently to minimize foam formation. The reconstituted solution in each vial contains 2100 U of conestat alfa, equivalent to 150 U/ml, and is clear and colorless.

The reconstituted solution in each vial should be inspected for particles and color changes. Do not use a solution that contains particles or color changes. This medicine should be used immediately.

Any unused medicine or waste material should be disposed of in accordance with local requirements.

Online doctors for RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION

Discuss questions about RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques. For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance. Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults. In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions. Patients commonly seek his care for: 

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Camera Book a video appointment
€80
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60
5.0 (2)
Doctor

Svetlana Kolomeeva

Cardiology 18 years exp.

Dr. Svetlana Kolomeeva is a general practitioner and internal medicine doctor providing online consultations for adults. She helps patients manage acute symptoms, chronic conditions, and preventive care. Her clinical focus includes cardiovascular health, hypertension control, and managing symptoms like fatigue, weakness, sleep issues, and overall low energy.

Patients commonly seek her help for:

  • High blood pressure, headaches, dizziness, swelling, palpitations.
  • Diagnosis and management of hypertension, arrhythmias, and tachycardia.
  • Metabolic syndrome, excess weight, high cholesterol.
  • Chronic fatigue, insomnia, poor concentration, anxiety.
  • Respiratory symptoms: colds, flu, sore throat, cough, fever.
  • Digestive issues: heartburn, bloating, constipation, IBS symptoms.
  • Chronic conditions: diabetes, thyroid disorders.
  • Interpretation of lab tests and medical reports, therapy adjustment.
  • Second opinion and decision-making support.
  • Cardiovascular disease prevention and metabolic risk reduction.
  • Long-term follow-up and dynamic health monitoring.

Dr Kolomeeva combines clinical expertise with personalised care. She clearly explains diagnoses, guides patients through symptoms and treatment options, and provides actionable plans. Her consultations are designed not only to address current complaints but also to stabilise chronic conditions and prevent future complications. She supports patients through every stage of care – from first symptoms to ongoing health management.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION?
RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION?
The active ingredient in RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION is conestat alfa. This information helps identify medicines with the same composition but different brand names.
Who manufactures RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION?
RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION is manufactured by Pharming Group N.V.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to RUCONEST 2100 U POWDER FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (conestat alfa) include RUCONEST 2100 U POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ANDEMBRY 200 mg INJECTABLE SOLUTION IN PRE-FILLED PEN, BERINERT 1500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media